The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

In this video, Halle C. F. Moore, MD, discusses the EMBER-3 study update evaluating imlunestrant for women with hormone receptor-positive, HER2-negative breast cancer, presented at San Antonio Breast ...

The Greater Philadelphia life sciences ecosystem has over 1,200 life sciences establishments, including 450 biotech research ...

In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval of pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia or small ...

Three stocks that did well during the last big bear market in 2022 are AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and ...

Policy swings have made it a slippery year for pharma ...

An updated edition of the October 28, 2025, article. The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement.

Eli Lilly and Company today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule ...

On conventional measures, the company’s shares look cheap. According to FactSet consensus forecasts, Novo trades on around 13 ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

The healthcare sector is entering the new year with a strong wind at its back. Visibility surrounding government healthcare policies has improved and investors are allocating more assets to the sector ...

Marathon Petroleum Corp. today announced that Maria A. Khoury will join the company as Executive Vice President and Chief Financial Officer, effective January 19, 2026. Khoury will succeed John J.